Zimmer Biomet has agreed to acquire Pacira BioSciences' FDA-cleared iovera pain relief device in a deal valued at up to $140 million, including $70 million upfront and future milestone payments. The agreement also includes a collaboration to advance the iovera spasticity program, extending Zimmer Biomet's reach into non-opioid pain management and neuromuscular conditions. The transaction is expected to close in the third quarter of 2026, subject to customary conditions. Zimmer Biomet's recently renewed $2.75 billion in revolving credit facilities provides liquidity to fund the acquisition alongside other corporate needs. The move reflects continued portfolio building around the full episode of orthopedic care, complementing its existing joint replacement and extremities products.
Pacira BioSciences, Inc.Pacira receives up to $140 million from Zimmer Biomet for its iovera device, including upfront and milestone payments.
Zimmer Biomet Holdings IncZimmer Biomet acquires FDA-cleared iovera device and collaborates on spasticity program, expanding into non-opioid pain management and neuromuscular conditions.